A multicentre, retrospective study for Nivolumab-refractory patients with advanced non-small-cell lung cancer
Latest Information Update: 18 Mar 2020
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Mar 2020 New trial record